Etomoxir, a carnitine palmitoyltransferase 1 inhibitor, combined with temozolomide reduces stemness and invasiveness in patient-derived glioblastoma tumorspheres

MLA

Jin-Kyoung Shim, et al. “Etomoxir, a Carnitine Palmitoyltransferase 1 Inhibitor, Combined with Temozolomide Reduces Stemness and Invasiveness in Patient-Derived Glioblastoma Tumorspheres.” Cancer Cell International, vol. 22, Oct. 2022. EBSCOhost, https://doi.org/10.1186/s12935-022-02731-7.

APA

Jin-Kyoung Shim, Seonah Choi, Seon-Jin Yoon, Ran Joo Choi, Junseong Park, Eun Hee Lee, Hye Joung Cho, Suji Lee, Wan-Yee Teo, Ju Hyung Moon, Hyun Sil Kim, Eui Hyun Kim, Jae-Ho Cheong, Jong Hee Chang, Jong In Yook, & Seok-Gu Kang. (2022). Etomoxir, a carnitine palmitoyltransferase 1 inhibitor, combined with temozolomide reduces stemness and invasiveness in patient-derived glioblastoma tumorspheres. Cancer Cell International, 22. https://doi.org/10.1186/s12935-022-02731-7

Chicago

Jin-Kyoung Shim, Seonah Choi, Seon-Jin Yoon, Ran Joo Choi, Junseong Park, Eun Hee Lee, Hye Joung Cho, et al. 2022. “Etomoxir, a Carnitine Palmitoyltransferase 1 Inhibitor, Combined with Temozolomide Reduces Stemness and Invasiveness in Patient-Derived Glioblastoma Tumorspheres.” Cancer Cell International 22 (October). doi:10.1186/s12935-022-02731-7.